Navigation Links
Misonix Appoints Stavros Vizirgianakis to Board of Directors
Date:5/10/2013

FARMINGDALE, N.Y., May 10, 2013 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, cranial maxillo – facial surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced today that Mr. Stavros Vizirgianakis has been appointed to the Misonix Board of Directors. The addition of Mr. Vizirgianakis expands the Misonix Board to seven members, with five members considered to be independent directors. Mr. Vizirgianakis is a Misonix shareholder, having acquired 5.3 percent of the Company's outstanding common stock in the open market in recent years.

Stavros Vizirgianakis has extensive medical device sales and marketing experience as a principal in Applied BioSurgical, a large medical device distributor in South Africa, and as a partner in MD Solutions Australasia PTY LTD, an Australian-based distributor of medical device products. Both companies are major distributors for a large number of medical device companies throughout the world.

Applied BioSurgical and MD Solutions have been exclusive distributors of Misonix products in their respective territories for many years. 

Mr. Michael A. McManus, Jr. , president and chief executive officer of Misonix, said, "We are very pleased to welcome Stavros Vizirgianakis to our Board of Directors. Stavros has a documented track record of success in marketing medical devices throughout the world.  I have gotten to know Stavros over the years as he has successfully sold our products internationally.  His industry knowledge, marketing experience, and his vast business relationships will be a great benefit to Misonix in the coming years."

About Misonix:
Misonix, Inc. designs, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

Private Securities Litigation Reform Act of 1995
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10 K, subsequent Quarterly Reports on Form 10 Q and Current Reports on Form 8 K.  The Company disclaims any obligation to update its forward looking relationships.Misonix Contact:

Investor Relations Contact:Richard Zaremba

Joe Diaz, Lytham Partners631 694 9555

602 889 9700invest@misonix.com

mson@lythampartners.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Reports Nine Months Fiscal 2013 Financial Results
2. Misonix Announces New Distribution Agreement For Denmark
3. Misonix Reports Financial Results for First Half of Fiscal 2013
4. Misonix Presents at MicroCapClub Invitational
5. Misonix Terminates Distribution Agreement With Aesculap
6. Misonix Reports Strong Revenue Increases for the First Quarter of Fiscal 2013
7. Misonix Reports Strong Revenue Increases for the Three Months and Full-Year Ended June 30, 2012
8. Misonix Product Featured At Neurosurgery Congress
9. Misonix Adds 6 Spine Sales Agencies In The U.S.
10. Misonix Attends International Meeting On Advanced Spine Techniques (IMAST) - Introduces New Product
11. Misonix Inks New Distribution Agreement For Croatia And Slovenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):